Literature DB >> 7500030

HLA-A2 subtypes are functionally distinct in peptide binding and presentation.

D Barouch1, T Friede, S Stevanović, L Tussey, K Smith, S Rowland-Jones, V Braud, A McMichael, H G Rammensee.   

Abstract

Nearly half of HLA-A2-positive individuals in African populations have a subtype of HLA-A2 other than the A*0201 allele. We have isolated the common African HLA-A2 subtype genes from Epstein-Barr virus-transformed B cell lines and have established stable class I reduced transfectants expressing these alleles. We have studied the peptide binding and presentation properties of A*0201, A*0202, A*0205, A*0214, and A*6901 by a combination of approaches: assaying direct binding of labeled synthetic peptides, studying the ability of antigen-specific cytotoxic T lymphocytes to recognize peptide-pulsed cells, and sequencing peptide pools and individual ligands eluted from cells. We find that A*0201-restricted peptides can also bind to A*0202 but do not bind strongly to the other alleles in this study. We show that some cytotoxic T lymphocytes can recognize all subtypes capable of binding an antigenic peptide, whereas others are subtype specific. Sequencing of eluted peptides reveals that A*0202 has a similar peptide motif to A*0201, but that A*0205, A*0214, and A*6901 have different motifs. These data strongly support a model in which residue 9 (Phe or Tyr) of the A2/A68/A69 molecules is a critical factor in determining the specificity of the B pocket of the major histocompatibility complex and the position 2 anchor residue of associated peptides. We conclude that a single-amino acid difference in the major histocompatibility complex can be sufficient to cause a dramatic change in the nature of bound peptides, implying that individuals with closely related HLA subtypes may present very different repertoires of antigenic peptides to T cells in an immune response. It is likely to be a general phenomenon that very similar class I subtypes will behave as functionally distinct HLA allotypes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7500030      PMCID: PMC2192253          DOI: 10.1084/jem.182.6.1847

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  52 in total

1.  Characterization of the HLA-A2.2 subtype: T cell evidence for further heterogeneity.

Authors:  F M Gotch; C Kelly; S A Ellis; L Wallace; A B Rickinson; J van der Poel; M J Crumpton; A J McMichael
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

2.  NK susceptibility varies inversely with target cell class I HLA antigen expression.

Authors:  W J Storkus; D N Howell; R D Salter; J R Dawson; P Cresswell
Journal:  J Immunol       Date:  1987-03-15       Impact factor: 5.422

3.  Diffraction methods for biological macromolecules. Interactive computer graphics: FRODO.

Authors:  T A Jones
Journal:  Methods Enzymol       Date:  1985       Impact factor: 1.600

4.  A monoclonal antibody that recognizes an antigenic determinant shared by HLA A2 and B17.

Authors:  A J McMichael; P Parham; N Rust; F Brodsky
Journal:  Hum Immunol       Date:  1980-09       Impact factor: 2.850

5.  Comparative structural analysis of HLA-A2 antigens distinguishable by cytotoxic T lymphocytes: variants M7 and DR1.

Authors:  M S Krangel; S Taketani; W E Biddison; D M Strong; J L Strominger
Journal:  Biochemistry       Date:  1982-11-23       Impact factor: 3.162

6.  Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28.

Authors:  P Parham; F M Brodsky
Journal:  Hum Immunol       Date:  1981-12       Impact factor: 2.850

7.  A human-hybridoma system based on a fast-growing mutant of the ARH-77 plasma cell leukemia-derived line.

Authors:  P A Edwards; C M Smith; A M Neville; M J O'Hare
Journal:  Eur J Immunol       Date:  1982-08       Impact factor: 5.532

8.  Recognition of HLA-B27 and related antigen by a monoclonal antibody.

Authors:  S A Ellis; C Taylor; A McMichael
Journal:  Hum Immunol       Date:  1982-08       Impact factor: 2.850

9.  Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis.

Authors:  C J Barnstable; W F Bodmer; G Brown; G Galfre; C Milstein; A F Williams; A Ziegler
Journal:  Cell       Date:  1978-05       Impact factor: 41.582

10.  The self determinants recognized by human virus-immune T cells can be distinguished from the serologically defined HLA antigens.

Authors:  W E Biddison; F E Ward; G M Shearer; S Shaw
Journal:  J Immunol       Date:  1980-02       Impact factor: 5.422

View more
  24 in total

1.  Heterozygote advantage fails to explain the high degree of polymorphism of the MHC.

Authors:  Rob J De Boer; José A M Borghans; Michiel van Boven; Can Keşmir; Franz J Weissing
Journal:  Immunogenetics       Date:  2004-01-13       Impact factor: 2.846

2.  MHC polymorphism under host-pathogen coevolution.

Authors:  José A M Borghans; Joost B Beltman; Rob J De Boer
Journal:  Immunogenetics       Date:  2004-01-13       Impact factor: 2.846

Review 3.  Structural and functional distinctiveness of HLA-A2 allelic variants.

Authors:  Kenneth Yuanxiang Chen; Jingxian Liu; Ee Chee Ren
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

4.  Identification and functional perspective of a novel HLA-A allele: A*0279.

Authors:  Fangfang Liu; Shan Wang; Yingjiang Ye; Huagang Zhang; Yu Zhang; Weifeng Chen
Journal:  Immunogenetics       Date:  2006-04-01       Impact factor: 2.846

5.  Full screening and accurate subtyping of HLA-A*02 alleles through group-specific amplification and mono-allelic sequencing.

Authors:  Shengli Song; Miaomiao Han; Han Zhang; Yuanxia Wang; Hong Jiang
Journal:  Cell Mol Immunol       Date:  2013-08-19       Impact factor: 11.530

Review 6.  Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands.

Authors:  Gabor Mester; Vanessa Hoffmann; Stefan Stevanović
Journal:  Cell Mol Life Sci       Date:  2011-03-09       Impact factor: 9.261

Review 7.  Class I HLA-restricted cytotoxic T lymphocyte responses against malaria--elucidation on the basis of HLA peptide binding motifs.

Authors:  D L Doolan; B Wizel; S L Hoffman
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

8.  Rapid definition of five novel HLA-A*3002-restricted human immunodeficiency virus-specific cytotoxic T-lymphocyte epitopes by elispot and intracellular cytokine staining assays.

Authors:  P J Goulder; M M Addo; M A Altfeld; E S Rosenberg; Y Tang; U Govender; N Mngqundaniso; K Annamalai; T U Vogel; M Hammond; M Bunce; H M Coovadia; B D Walker
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

Review 9.  The human leukocyte antigen class I genes in nasopharyngeal carcinoma risk.

Authors:  Elham Hassen; Ghandri Nahla; Noureddine Bouaouina; Lotfi Chouchane
Journal:  Mol Biol Rep       Date:  2009-05-17       Impact factor: 2.316

10.  Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival.

Authors:  William E Carson; Joseph M Unger; Jeffrey A Sosman; Lawrence E Flaherty; Ralph J Tuthill; Mark J Porter; John A Thompson; Raymond A Kempf; Megan Othus; Antoni Ribas; Vernon K Sondak
Journal:  Cancer Immunol Res       Date:  2014-07-03       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.